Linagliptin
- Generic Name
- Linagliptin
- Brand Names
- Glyxambi, Jentadueto, Tradjenta, Trajenta, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N8O2
- CAS Number
- 668270-12-0
- Unique Ingredient Identifier
- 3X29ZEJ4R2
- Background
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
- Indication
Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise. It should not be used to treat type I diabetes or in diabetic ketoacidosis. An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise.
- Associated Conditions
- Type 2 Diabetes Mellitus
Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency
- Conditions
- Type2 Diabetes MellitusRenal InsufficiencyAlbuminuria
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 209
- Registration Number
- NCT03667300
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Efficacy and Safety of Empagliflozin in NODAT
- Conditions
- Kidney Transplant; ComplicationsNew Onset Diabetes After Transplant
- Interventions
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT03642184
- Locations
- 🇨🇳
Department of nephrology, endocrinology and kidney transplantation , Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT03629054
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)
- Conditions
- Diabetic Nephropathy Type 2
- Interventions
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Registration Number
- NCT03504566
- Locations
- 🇩🇰
Steno Diabetes Center Copenhagen, Gentofte, Denmark
Contrast Nephropathy in Type 2 Diabetes
- Conditions
- Kidney Function Affection Upon Exposure to RadiocontrastDiabetesMicroalbuminuria
- Interventions
- First Posted Date
- 2018-03-20
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Fayoum University
- Target Recruit Count
- 40
- Registration Number
- NCT03470454
- Locations
- 🇪🇬
Faculty of medicine Fayoum univesity, Fayoum, Egypt
🇪🇬Fayoum University, Fayoum, Egypt
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 175
- Registration Number
- NCT03429543
- Locations
- 🇺🇸
Children's Center for Advanced Pediatrics, Atlanta, Georgia, United States
🇺🇸Atlanta Center, Atlanta, Georgia, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
Real World Glycemic Effectiveness of Linagliptin
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 11001
- Registration Number
- NCT03338803
- Locations
- 🇺🇸
Optum, Eden Prairie, Minnesota, United States
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Other: Radiation
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 314
- Registration Number
- NCT03337698
- Locations
- 🇺🇸
Christiana Care Health Services, Newark, Delaware, United States
🇺🇸Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas, Nevada, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy
- Conditions
- Peritoneal DialysisType 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2017-10-24
- Lead Sponsor
- Yanbing Li
- Target Recruit Count
- 232
- Registration Number
- NCT03320031
- Locations
- 🇨🇳
endocrinology department of the first affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
- Conditions
- Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
- Interventions
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 410
- Registration Number
- NCT03281369
- Locations
- 🇦🇺
Blacktown Hospital, Blacktown, New South Wales, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇮🇱Rambam Health Care Campus, Haifa, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.